vs

Side-by-side financial comparison of MADRIGAL PHARMACEUTICALS, INC. (MDGL) and UNISYS CORP (UIS). Click either name above to swap in a different company.

UNISYS CORP is the larger business by last-quarter revenue ($574.5M vs $321.1M, roughly 1.8× MADRIGAL PHARMACEUTICALS, INC.). UNISYS CORP runs the higher net margin — 3.3% vs -18.2%, a 21.5% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 5.3%). UNISYS CORP produced more free cash flow last quarter ($97.3M vs $-133.8M).

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

Unisys Corporation is a technology company founded in 1986 and headquartered in Blue Bell, Pennsylvania. The company provides cloud, AI, digital workplace, logistics, and enterprise computing services.

MDGL vs UIS — Head-to-Head

Bigger by revenue
UIS
UIS
1.8× larger
UIS
$574.5M
$321.1M
MDGL
Growing faster (revenue YoY)
MDGL
MDGL
+205.4% gap
MDGL
210.8%
5.3%
UIS
Higher net margin
UIS
UIS
21.5% more per $
UIS
3.3%
-18.2%
MDGL
More free cash flow
UIS
UIS
$231.2M more FCF
UIS
$97.3M
$-133.8M
MDGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MDGL
MDGL
UIS
UIS
Revenue
$321.1M
$574.5M
Net Profit
$-58.6M
$18.7M
Gross Margin
33.9%
Operating Margin
-18.6%
13.3%
Net Margin
-18.2%
3.3%
Revenue YoY
210.8%
5.3%
Net Profit YoY
1.4%
-37.7%
EPS (diluted)
$-2.55
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MDGL
MDGL
UIS
UIS
Q4 25
$321.1M
$574.5M
Q3 25
$287.3M
$460.2M
Q2 25
$212.8M
$483.3M
Q1 25
$137.3M
$432.1M
Q4 24
$103.3M
$545.4M
Q3 24
$62.2M
$497.0M
Q2 24
$478.2M
Q1 24
$0
$487.8M
Net Profit
MDGL
MDGL
UIS
UIS
Q4 25
$-58.6M
$18.7M
Q3 25
$-114.2M
$-308.9M
Q2 25
$-42.3M
$-20.1M
Q1 25
$-73.2M
$-29.5M
Q4 24
$-59.4M
$30.0M
Q3 24
$-107.0M
$-61.9M
Q2 24
$-12.0M
Q1 24
$-147.5M
$-149.5M
Gross Margin
MDGL
MDGL
UIS
UIS
Q4 25
33.9%
Q3 25
25.5%
Q2 25
26.9%
Q1 25
96.7%
24.9%
Q4 24
32.1%
Q3 24
29.2%
Q2 24
27.2%
Q1 24
27.9%
Operating Margin
MDGL
MDGL
UIS
UIS
Q4 25
-18.6%
13.3%
Q3 25
-39.7%
-7.3%
Q2 25
-22.2%
6.3%
Q1 25
-57.8%
1.2%
Q4 24
-64.8%
8.9%
Q3 24
-187.1%
1.5%
Q2 24
4.9%
Q1 24
3.6%
Net Margin
MDGL
MDGL
UIS
UIS
Q4 25
-18.2%
3.3%
Q3 25
-39.8%
-67.1%
Q2 25
-19.9%
-4.2%
Q1 25
-53.4%
-6.8%
Q4 24
-57.5%
5.5%
Q3 24
-172.0%
-12.5%
Q2 24
-2.5%
Q1 24
-30.6%
EPS (diluted)
MDGL
MDGL
UIS
UIS
Q4 25
$-2.55
$0.24
Q3 25
$-5.08
$-4.33
Q2 25
$-1.90
$-0.28
Q1 25
$-3.32
$-0.42
Q4 24
$-2.50
$0.45
Q3 24
$-4.92
$-0.89
Q2 24
$-0.17
Q1 24
$-7.38
$-2.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MDGL
MDGL
UIS
UIS
Cash + ST InvestmentsLiquidity on hand
$198.7M
$413.9M
Total DebtLower is stronger
$339.9M
$729.0M
Stockholders' EquityBook value
$602.7M
$-282.6M
Total Assets
$1.3B
$1.8B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MDGL
MDGL
UIS
UIS
Q4 25
$198.7M
$413.9M
Q3 25
$295.7M
$321.9M
Q2 25
$186.2M
$300.8M
Q1 25
$183.6M
$393.1M
Q4 24
$100.0M
$376.5M
Q3 24
$232.7M
$373.7M
Q2 24
$344.9M
Q1 24
$622.5M
$382.8M
Total Debt
MDGL
MDGL
UIS
UIS
Q4 25
$339.9M
$729.0M
Q3 25
$339.8M
$723.2M
Q2 25
$118.4M
$692.7M
Q1 25
$118.0M
$488.3M
Q4 24
$117.6M
$488.2M
Q3 24
$117.1M
$488.5M
Q2 24
$489.2M
Q1 24
$116.1M
$488.4M
Stockholders' Equity
MDGL
MDGL
UIS
UIS
Q4 25
$602.7M
$-282.6M
Q3 25
$625.7M
$-300.2M
Q2 25
$696.0M
$-221.5M
Q1 25
$710.6M
$-267.8M
Q4 24
$754.4M
$-283.4M
Q3 24
$777.2M
$-202.2M
Q2 24
$-174.1M
Q1 24
$850.8M
$-158.6M
Total Assets
MDGL
MDGL
UIS
UIS
Q4 25
$1.3B
$1.8B
Q3 25
$1.4B
$1.7B
Q2 25
$1.0B
$1.8B
Q1 25
$996.6M
$1.8B
Q4 24
$1.0B
$1.9B
Q3 24
$1.1B
$1.9B
Q2 24
$1.9B
Q1 24
$1.1B
$1.9B
Debt / Equity
MDGL
MDGL
UIS
UIS
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MDGL
MDGL
UIS
UIS
Operating Cash FlowLast quarter
$-133.5M
$104.9M
Free Cash FlowOCF − Capex
$-133.8M
$97.3M
FCF MarginFCF / Revenue
-41.7%
16.9%
Capex IntensityCapex / Revenue
0.1%
1.3%
Cash ConversionOCF / Net Profit
5.61×
TTM Free Cash FlowTrailing 4 quarters
$-170.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MDGL
MDGL
UIS
UIS
Q4 25
$-133.5M
$104.9M
Q3 25
$79.8M
$38.0M
Q2 25
$-47.1M
$-316.2M
Q1 25
$-88.9M
$33.3M
Q4 24
$-104.5M
$76.6M
Q3 24
$-67.0M
$32.0M
Q2 24
$2.7M
Q1 24
$-149.2M
$23.8M
Free Cash Flow
MDGL
MDGL
UIS
UIS
Q4 25
$-133.8M
$97.3M
Q3 25
$79.0M
$32.4M
Q2 25
$-324.1M
Q1 25
$24.4M
Q4 24
$-104.7M
$66.5M
Q3 24
$-67.8M
$25.2M
Q2 24
$-6.0M
Q1 24
$-149.5M
$17.1M
FCF Margin
MDGL
MDGL
UIS
UIS
Q4 25
-41.7%
16.9%
Q3 25
27.5%
7.0%
Q2 25
-67.1%
Q1 25
5.6%
Q4 24
-101.3%
12.2%
Q3 24
-109.0%
5.1%
Q2 24
-1.3%
Q1 24
3.5%
Capex Intensity
MDGL
MDGL
UIS
UIS
Q4 25
0.1%
1.3%
Q3 25
0.3%
1.2%
Q2 25
0.0%
1.6%
Q1 25
0.0%
2.1%
Q4 24
0.2%
1.9%
Q3 24
1.3%
1.4%
Q2 24
1.8%
Q1 24
1.4%
Cash Conversion
MDGL
MDGL
UIS
UIS
Q4 25
5.61×
Q3 25
Q2 25
Q1 25
Q4 24
2.55×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

UIS
UIS

Segment breakdown not available.

Related Comparisons